课题基金 / 基金详情

Project 3: Inhibition of radiation-induced phenotype conversion in glioblastoma

Project 3: Inhibition of radiation-induced phenotype conversion in glioblastoma
项目3:抑制放射诱导的胶质母细胞瘤表型转换
批准号:
9752977
负责人:
Frank Pajonk
金额:
$34.58万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:

项目摘要

项目成果

Frank Pajonk的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project 3: Inhibition of radiation-induced phenotype conversion in glioblastoma SUMMARY/ABSTRACT Despite a tremendous effort in basic science, clinical trials, drug development, and technical advances in surgery and radiation oncology, glioblastoma remains incurable and improvements in overall survival have been marginal. While radiotherapy is still one of the most effective treatment options for glioblastoma, it cannot control the disease over time. This led us to conclude that novel combination therapies are desperately needed to improve radiation treatment outcome for patients suffering from this disease. The studies outlined in this proposal are based on a hypothesis that is backed by our extensive preliminary data and rigorous published data in the literature. Specifically, we hypothesize that radiation causes a phenotype conversion of differentiated glioma cells into therapy-resistant glioma-initiating cells (GICs), and that interfering with this process will increase the efficiency of radiotherapy. The three aims of this study will address this aspect of glioma biology using an innovative tool to track GICs and their progeny, while leveraging the unique resources and expertise available in the proposed UCLA SPORE in Brain Cancer. In Aim 1, we will study spontaneous and radiation-induced phenotype conversion in glioblastoma under different microenvironmental conditions, and determine if this process generates tumorigenic GICs in vitro and in vivo. In Aim 2, we will attempt to prevent phenotype conversion of non-tumorigenic cells into GICs using dopamine receptor antagonists. Finally, in Aim 3, we propose a novel clinical trial to test whether quetiapine, a dopamine receptor antagonist, can reduce the number of GICs in patients with recurrent GBM and prolong their survival. If successful, results from these studies could have a wider impact on cancer, as these principles may apply not only to glioblastoma but to many other solid tumors.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Utilizing Radiation-Induced Multi-potency to Increase the Efficacy of Radiotherapy
Use of CTEP portfolio compounds to counteract phenotype conversion in GBM
Use of CTEP portfolio compounds to counteract phenotype conversion in GBM
Use of CTEP portfolio compounds to counteract phenotype conversion in GBM
海外基金